Smart Dosimetry System (SDS) Accepted into National NSF I-Corps Program
The program awards $50,000 to advance groundbreaking technologies through intensive customer discovery and market validation.
Penn Medicine researchers use AI to uncover potential antibiotic compounds
The researchers used AI to analyze the genomes of tens of thousands of bacteria and other primitive organisms.
New Mini-documentary Showcases the Path to CAR-T Cell Therapy
This short documentary tells the powerful story of Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at Penn Medicine, and the successful use of CAR-T cell therapy.
Penn Medicine Highlights Public Funding’s Role in Translating Scientific Discoveries into Life-Saving Treatments
Stephen Bagley, MD, MSCE, Assistant Professor of Hematology-Oncology and Neurosurgery at Penn Medicine, discusses how he used CAR T cell therapy to shrink a patient's tumor.
Nicholas Siciliano, Chief Executive Officer and Co-Founder of Penn Spinout ViTToria Biotherapeutics, Wins the Science Center’s 2025 Commercialization Award
Siciliano won the Science Center’s 2025 Commercialization Award in recognition of his outstanding contributions to the commercialization of innovative science and technology.
Apellis’ Empaveli® Gains FDA Approval for Broader Rare Kidney Disease Use
Penn spinout Apellis received FDA approval for an expanded label for Empaveli®.
Carisma Therapeutics Enters into Definitive Merger Agreement with OrthoCellix to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
Carisma Therapeutics, co-founded by Saar Gill, MD, PhD, Associate Professor of Medicine at Penn Medicine, is merging with OrthoCellix.
Jim Wilson’s Gemma Biotherapeutics Enters into Partnership with the Abu Dhabi Department of Health and Purehealth to Advance Global Access to Gene Therapies for Rare Diseases
Gemma plans to establish manufacturing and research centers in Abu Dhabi.
Penn Spinout Dispatch Bio Emerges from Stealth Mode with $216M in Funding
Dispatch Bio, co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine, is developing a universal cancer treatment for solid tumors.
Penn Spinout Interius Therapeutics To Be Acquired by Kite Therapeutics for $350M
Kite Therapeutics, a Gilead Company, has entered into a definitive agreement to acquire Interius Therapeutics .